Literature DB >> 16859853

Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS.

L Coward1, G Gorman, P Noker, C Kerstner-Wood, M Pellecchia, J C Reed, L Jia.   

Abstract

A simple and selective liquid chromatography/tandem mass spectrometry (LC/MS/MS) method based on internal standard quantitation using apigenin as the internal standard has been developed and validated for the analysis of the gossypol analog apogossypol, a pro-apoptotic compound, in mouse plasma. The methodology involves protein precipitation of plasma samples followed by LC/MS/MS analysis. Ascorbic acid was added to the spiking solutions and plasma samples to stabilize the easily oxidized compound. Separation of apogossypol and the internal standard from the plasma matrix was achieved using a C18 column with a gradient elution profile consisting of 5mM ammonium acetate and methanol. The validated range of the method extended from 10 to 2000 ng/mL with accuracies of 85-115% and precision of <15%. The average recovery of apogossypol at three concentrations (50, 200 and 1000 ng/mL) assayed in triplicate using this methodology was determined to be 90.8+/-12.9%. Recovery for the internal standard (apigenin) at a concentration of 500 ng/mL was found to be 99.9+/-6.41%. Apogossypol concentrations of 50 ng/mL and above were found to be stable in extracted plasma for 24h when stored at 25 degrees C. This method has been applied to the determination of apogossypol concentrations in plasma collected from mice given an IV dose of apogossypol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859853     DOI: 10.1016/j.jpba.2006.05.020

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  12 in total

1.  BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Authors:  Jun Wei; John L Stebbins; Shinichi Kitada; Rupesh Dash; William Placzek; Michele F Rega; Bainan Wu; Jason Cellitti; Dayong Zhai; Li Yang; Russell Dahl; Paul B Fisher; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

2.  Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Authors:  Jun Wei; Shinichi Kitada; John L Stebbins; William Placzek; Dayong Zhai; Bainan Wu; Michele F Rega; Ziming Zhang; Jason Cellitti; Li Yang; Russell Dahl; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2010-10-29       Impact factor: 7.446

3.  Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins.

Authors:  Jun Wei; Shinichi Kitada; Michele F Rega; Aras Emdadi; Hongbin Yuan; Jason Cellitti; John L Stebbins; Dayong Zhai; Jiazhi Sun; Li Yang; Russell Dahl; Ziming Zhang; Bainan Wu; Si Wang; Tyler A Reed; Hong-Gang Wang; Nicholas Lawrence; Said Sebti; John C Reed; Maurizio Pellecchia
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 4.  Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.

Authors:  Naval Bajwa; Chenzhong Liao; Zaneta Nikolovska-Coleska
Journal:  Expert Opin Ther Pat       Date:  2011-12-23       Impact factor: 6.674

5.  A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies.

Authors:  Hongxia Lin; Murugesan K Gounder; Joseph R Bertino; Ah-Ng Tony Kong; Robert S DiPaola; Mark N Stein
Journal:  J Pharm Biomed Anal       Date:  2012-03-24       Impact factor: 3.935

6.  A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Authors:  Greg S Gorman; Lori U Coward; Lea Freeman; Pat E Noker; Craig W Beattie; Lee Jia
Journal:  J Pharm Biomed Anal       Date:  2010-06-30       Impact factor: 3.935

7.  Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).

Authors:  Shinichi Kitada; Christina L Kress; Maryla Krajewska; Lee Jia; Maurizio Pellecchia; John C Reed
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

8.  Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.

Authors:  Roger S Jackson; William Placzek; Ana Fernandez; Shabnam Ziaee; Chia-Yi Chu; Jun Wei; John Stebbins; Shinichi Kitada; Gloria Fritz; John C Reed; Leland W Chung; Maurizio Pellecchia; Neil A Bhowmick
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

9.  Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists.

Authors:  Jun Wei; Michele F Rega; Shinichi Kitada; Hongbin Yuan; Dayong Zhai; Prabhakar Risbood; Herbert H Seltzman; Charles E Twine; John C Reed; Maurizio Pellecchia
Journal:  Cancer Lett       Date:  2008-09-07       Impact factor: 8.679

10.  Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Authors:  Jun Wei; Shinichi Kitada; Michele F Rega; John L Stebbins; Dayong Zhai; Jason Cellitti; Hongbin Yuan; Aras Emdadi; Russell Dahl; Ziming Zhang; Li Yang; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.